Overview
Ncage Therapeutics is developing synthetic protein cages based on the bacterial TRAP protein, which can display biological material or transport molecules like nucleic acids and proteins into cells. Their platform includes programmable opening and closing features for loading and releasing cargo, such as proteins and small molecule drugs. The company focuses on applications in synthetic viral-like particle vaccines and enhancing the safety profile of antibody-drug conjugates for cancer treatment.
Financials
The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2021-03-01. Active
08 1160 2202 0000 0004 5911 3688
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
4 public aid cases recorded, with a total value of $4,749,467.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Dec 1, 2023 | Aid for SME access to finance — risk finance aid | $2.4M$2,380,060 | PFR Ventures sp. z o.o. | |
| Jun 26, 2020 | Aid for research and development projects: industrial research | $1.5M$1,528,540 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Jun 26, 2020 | Aid for research and development projects: experimental development | $834.5K$834,456 | Dyrektor Narodowego Centrum Badań i Rozwoju |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
If the management board is a multi-member management board, the President of the Management Board acting jointly with a commercial proxy, the President of the Management Board acting jointly with another member of the management board, or two members of the management board acting jointly, is authorized to submit declarations of will on behalf of the company; if a Vice-President of the Management Board for financial matters is appointed, the company is represented by a member of the management board or the President of the Management Board acting jointly with the Vice-President of the Management Board for financial matters.
Supervisory board
Beneficial owners
| Person | Rights | |
|---|---|---|
Jonathan Heddle (51)  | Shareholder of a joint-stock company, 25.76% | |
Christopher Lewis Kaplan (66)  | Shareholder of a joint-stock company, 20.37%; Christopher kaplan posiada 60 udziałów stanowiących 60% wszystkich udziałów oraz jest jedynym członkiem zarządu spółki axcend health sp. z o.o., która posiada 22,94% procent akcji w kapitale spółki ncage therapeutics s.a. |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| NanotheaS.A. | $115.78 | nanothea.com | ||
| MolecureS.A. | $10.77 | molecure.com |
FAQ
Last updated: 2026-04-03